These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 19019674)

  • 1. Fragment-based discovery of JAK-2 inhibitors.
    Antonysamy S; Hirst G; Park F; Sprengeler P; Stappenbeck F; Steensma R; Wilson M; Wong M
    Bioorg Med Chem Lett; 2009 Jan; 19(1):279-82. PubMed ID: 19019674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.
    Schenkel LB; Huang X; Cheng A; Deak HL; Doherty E; Emkey R; Gu Y; Gunaydin H; Kim JL; Lee J; Loberg R; Olivieri P; Pistillo J; Tang J; Wan Q; Wang HL; Wang SW; Wells MC; Wu B; Yu V; Liu L; Geuns-Meyer S
    J Med Chem; 2011 Dec; 54(24):8440-50. PubMed ID: 22087750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
    Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors.
    Wang T; Ledeboer MW; Duffy JP; Salituro FG; Pierce AC; Zuccola HJ; Block E; Shlyakter D; Hogan JK; Bennani YL
    Bioorg Med Chem Lett; 2010 Jan; 20(1):153-6. PubMed ID: 19945871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design.
    Hohwy M; Spadola L; Lundquist B; Hawtin P; Dahmén J; Groth-Clausen I; Nilsson E; Persdotter S; von Wachenfeldt K; Folmer RH; Edman K
    J Med Chem; 2008 Apr; 51(7):2178-86. PubMed ID: 18341273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B.
    Collins I; Caldwell J; Fonseca T; Donald A; Bavetsias V; Hunter LJ; Garrett MD; Rowlands MG; Aherne GW; Davies TG; Berdini V; Woodhead SJ; Davis D; Seavers LC; Wyatt PG; Workman P; McDonald E
    Bioorg Med Chem; 2006 Feb; 14(4):1255-73. PubMed ID: 16249095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors.
    Ioannidis S; Lamb ML; Davies AM; Almeida L; Su M; Bebernitz G; Ye M; Bell K; Alimzhanov M; Zinda M
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6524-8. PubMed ID: 19857966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragment-based ligand discovery.
    Fischer M; Hubbard RE
    Mol Interv; 2009 Feb; 9(1):22-30. PubMed ID: 19299661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination.
    Griffin RJ; Henderson A; Curtin NJ; Echalier A; Endicott JA; Hardcastle IR; Newell DR; Noble ME; Wang LZ; Golding BT
    J Am Chem Soc; 2006 May; 128(18):6012-3. PubMed ID: 16669651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two 'Golden Ratio' indices in fragment-based drug discovery.
    Orita M; Ohno K; Niimi T
    Drug Discov Today; 2009 Mar; 14(5-6):321-8. PubMed ID: 19028598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and optimization of p38 inhibitors via computer-assisted drug design.
    Goldberg DR; Hao MH; Qian KC; Swinamer AD; Gao DA; Xiong Z; Sarko C; Berry A; Lord J; Magolda RL; Fadra T; Kroe RR; Kukulka A; Madwed JB; Martin L; Pargellis C; Skow D; Song JJ; Tan Z; Torcellini CA; Zimmitti CS; Yee NK; Moss N
    J Med Chem; 2007 Aug; 50(17):4016-26. PubMed ID: 17658737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase.
    van Linden OP; Farenc C; Zoutman WH; Hameetman L; Wijtmans M; Leurs R; Tensen CP; Siegal G; de Esch IJ
    Eur J Med Chem; 2012 Jan; 47(1):493-500. PubMed ID: 22137457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery.
    Erlanson DA; Arndt JW; Cancilla MT; Cao K; Elling RA; English N; Friedman J; Hansen SK; Hession C; Joseph I; Kumaravel G; Lee WC; Lind KE; McDowell RS; Miatkowski K; Nguyen C; Nguyen TB; Park S; Pathan N; Penny DM; Romanowski MJ; Scott D; Silvian L; Simmons RL; Tangonan BT; Yang W; Sun L
    Bioorg Med Chem Lett; 2011 May; 21(10):3078-83. PubMed ID: 21459573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of spirocyclic sulfonamides as potent Akt inhibitors with exquisite selectivity against PKA.
    Xu R; Banka A; Blake JF; Mitchell IS; Wallace EM; Bencsik JR; Kallan NC; Spencer KL; Gloor SL; Martinson M; Risom T; Gross SD; Morales TH; Wu WI; Vigers GP; Brandhuber BJ; Skelton NJ
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2335-40. PubMed ID: 21420856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches.
    Vieth M; Erickson J; Wang J; Webster Y; Mader M; Higgs R; Watson I
    J Med Chem; 2009 Oct; 52(20):6456-66. PubMed ID: 19791746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.
    Wyss DF; Wang YS; Eaton HL; Strickland C; Voigt JH; Zhu Z; Stamford AW
    Top Curr Chem; 2012; 317():83-114. PubMed ID: 21647837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of Free-Wilson selectivity analysis for combinatorial library design.
    Sciabola S; Stanton RV; Johnson TL; Xi H
    Methods Mol Biol; 2011; 685():91-109. PubMed ID: 20981520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and PKCtheta inhibitory activity of a series of 5-vinyl phenyl sulfonamide-3-pyridinecarbonitriles.
    Shim J; Eid C; Lee J; Liu E; Chaudhary D; Boschelli DH
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6575-7. PubMed ID: 19854645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progress in fragment-based lead discovery.
    Schulz MN; Hubbard RE
    Curr Opin Pharmacol; 2009 Oct; 9(5):615-21. PubMed ID: 19477685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.
    Labadie S; Dragovich PS; Barrett K; Blair WS; Bergeron P; Chang C; Deshmukh G; Eigenbrot C; Ghilardi N; Gibbons P; Hurley CA; Johnson A; Kenny JR; Kohli PB; Kulagowski JJ; Liimatta M; Lupardus PJ; Mendonca R; Murray JM; Pulk R; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward S; Zak M
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7627-33. PubMed ID: 23107482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.